Search by Drug Name or NDC
NDC 25021-0207-51 doxorubicin hydrochloride 2 mg/mL Details
doxorubicin hydrochloride 2 mg/mL
doxorubicin hydrochloride is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Sagent Pharmaceuticals. The primary component is DOXORUBICIN HYDROCHLORIDE.
MedlinePlus Drug Summary
Doxorubicin is used in combination with other medications to treat certain types of bladder, breast, lung, stomach, and ovarian cancer; Hodgkin's lymphoma (Hodgkin's disease) and non-Hodgkin's lymphoma (cancer that begins in the cells of the immune system); and certain types of leukemia (cancer of the white blood cells), including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML, ANLL). Doxorubicin is also used alone and in combination with other medications to treat certain types of thyroid cancer and certain types of soft tissue or bone sarcomas (cancer that forms in muscles and bones). It is also used to treat neuroblastoma (a cancer that begins in nerve cells and occurs mainly in children) and Wilms' tumor (a type of kidney cancer that occurs in children). Doxorubicin is in a class of medications called anthracyclines. It works by slowing or stopping the growth of cancer cells in your body.
Related Packages: 25021-0207-51Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Doxorubicin
Product Information
| NDC | 25021-0207 |
|---|---|
| Product ID | 25021-207_ecebeba3-8ead-4c7f-b22c-fdcf977adfe6 |
| Associated GPIs | 21200040102010 |
| GCN Sequence Number | 061483 |
| GCN Sequence Number Description | doxorubicin HCl VIAL 10 MG/5 ML INTRAVEN |
| HIC3 | V1D |
| HIC3 Description | ANTIBIOTIC ANTINEOPLASTICS |
| GCN | 97271 |
| HICL Sequence Number | 003916 |
| HICL Sequence Number Description | DOXORUBICIN HCL |
| Brand/Generic | Generic |
| Proprietary Name | doxorubicin hydrochloride |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | doxorubicin hydrochloride |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 2 |
| Active Ingredient Units | mg/mL |
| Substance Name | DOXORUBICIN HYDROCHLORIDE |
| Labeler Name | Sagent Pharmaceuticals |
| Pharmaceutical Class | Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA209825 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 25021-0207-51 (25021020751)
| NDC Package Code | 25021-207-51 |
|---|---|
| Billing NDC | 25021020751 |
| Package | 1 VIAL in 1 CARTON (25021-207-51) / 100 mL in 1 VIAL |
| Marketing Start Date | 2013-10-31 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |